138 related articles for article (PubMed ID: 14584798)
1. A new paclitaxel prodrug for use in ADEPT strategy.
Bouvier E; Thirot S; Schmidt F; Monneret C
Org Biomol Chem; 2003 Oct; 1(19):3343-52. PubMed ID: 14584798
[TBL] [Abstract][Full Text] [Related]
2. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of prodrugs based on the natural antibiotic duocarmycin for use in ADEPT and PMT.
Tietze LF; Schmuck K; Schuster HJ; Müller M; Schuberth I
Chemistry; 2011 Feb; 17(6):1922-9. PubMed ID: 21274943
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological activity of beta-glucuronyl carbamate-based prodrugs of paclitaxel as potential candidates for ADEPT.
de Bont DB; Leenders RG; Haisma HJ; van der Meulen-Muileman I; Scheeren HW
Bioorg Med Chem; 1997 Feb; 5(2):405-14. PubMed ID: 9061205
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
6. Development of first photoresponsive prodrug of paclitaxel.
Skwarczynski M; Noguchi M; Hirota S; Sohma Y; Kimura T; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2006 Sep; 16(17):4492-6. PubMed ID: 16806915
[TBL] [Abstract][Full Text] [Related]
7. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
8. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release.
de Groot FM; Loos WJ; Koekkoek R; van Berkom LW; Busscher GF; Seelen AE; Albrecht C; de Bruijn P; Scheeren HW
J Org Chem; 2001 Dec; 66(26):8815-30. PubMed ID: 11749612
[TBL] [Abstract][Full Text] [Related]
9. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
Tietze LF; Schmuck K
Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
[TBL] [Abstract][Full Text] [Related]
10. Glucuronides in anti-cancer therapy.
Chen X; Wu B; Wang PG
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):139-50. PubMed ID: 12678908
[TBL] [Abstract][Full Text] [Related]
11. Beta-galactoside prodrugs of doxorubicin for application in antibody directed enzyme prodrug therapy/prodrug monotherapy.
Devalapally H; Navath RS; Yenamandra V; Akkinepally RR; Devarakonda RK
Arch Pharm Res; 2007 Jun; 30(6):723-32. PubMed ID: 17679550
[TBL] [Abstract][Full Text] [Related]
12. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
[TBL] [Abstract][Full Text] [Related]
13. Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug.
Schmidt F; Monneret C
Bioorg Med Chem; 2003 May; 11(10):2277-83. PubMed ID: 12713838
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.
de Groot FM; van Berkom LW; Scheeren HW
J Med Chem; 2000 Aug; 43(16):3093-102. PubMed ID: 10956217
[TBL] [Abstract][Full Text] [Related]
16. Modulating paclitaxel bioavailability for targeting prostate cancer.
Kumar SK; Williams SA; Isaacs JT; Denmeade SR; Khan SR
Bioorg Med Chem; 2007 Jul; 15(14):4973-84. PubMed ID: 17502149
[TBL] [Abstract][Full Text] [Related]
17. First enzymatically activated Taxotere prodrugs designed for ADEPT and PMT.
Bouvier E; Thirot S; Schmidt F; Monneret C
Bioorg Med Chem; 2004 Mar; 12(5):969-77. PubMed ID: 14980610
[TBL] [Abstract][Full Text] [Related]
18. A new spacer group derived from arylmalonaldehydes for glucuronylated prodrugs.
Papot S; Combaud D; Gesson JP
Bioorg Med Chem Lett; 1998 Sep; 8(18):2545-8. PubMed ID: 9873577
[TBL] [Abstract][Full Text] [Related]
19. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
20. Water-soluble prodrugs of paclitaxel containing self-immolative disulfide linkers.
Gund M; Khanna A; Dubash N; Damre A; Singh KS; Satyam A
Bioorg Med Chem Lett; 2015 Jan; 25(1):122-7. PubMed ID: 25466201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
